- Colgate-Palmolive recently announced its second-quarter 2025 results, reporting sales of US$5.11 billion and net income of US$743 million, alongside the completion of a repurchase of over 2.83 million shares for US$257.16 million.
- The company reaffirmed its full-year 2025 guidance, highlighting expectations for low single-digit net sales growth and noting the impact of exiting private label pet sales and foreign exchange pressures.
- We’ll examine how the updated sales guidance and ongoing share buybacks factor into Colgate-Palmolive’s forward-looking investment narrative.
We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Colgate-Palmolive Investment Narrative Recap
To be a Colgate-Palmolive shareholder, you need to believe in the resilience of its global brands and ability to drive steady organic growth, even as the company faces pressures from cautious consumer spending and ongoing cost inflation. The recent Q2 results and 2025 sales guidance are consistent with this narrative, confirming that foreign exchange headwinds and the exit from private label pet sales are expected to limit short-term sales growth, but do not pose a material shift to the core story. The primary risk to monitor remains the impact of sustained cost pressures on profit margins, while the most important short-term catalyst continues to be successful premiumization and growth in emerging markets.
The share buyback announcement, completion of 2.83 million repurchased shares for over US$257 million, stands out as the most relevant recent update linked to this quarterly news. It adds to shareholder value and underscores management's ongoing confidence in the business’s cash generation and its commitment to returning capital. While this capital return is supportive, it does not fundamentally alter near-term catalysts or headline risks related to margin pressures and volume growth in key markets.
Yet, in contrast to these sources of stability, investors should be aware that persistent inflation in raw material costs could...
Read the full narrative on Colgate-Palmolive (it's free!)
Colgate-Palmolive's narrative projects $22.4 billion in revenue and $3.5 billion in earnings by 2028. This requires 3.9% yearly revenue growth and a $0.6 billion increase in earnings from the current $2.9 billion level.
Uncover how Colgate-Palmolive's forecasts yield a $95.06 fair value, a 12% upside to its current price.
Exploring Other Perspectives
Six community-driven fair value estimates for Colgate-Palmolive range from US$60.84 to US$129.42. With ongoing raw material cost inflation pressuring margins, these viewpoints reveal how market participants weigh earnings quality against potential risks to profitability.
Explore 6 other fair value estimates on Colgate-Palmolive - why the stock might be worth as much as 52% more than the current price!
Build Your Own Colgate-Palmolive Narrative
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Colgate-Palmolive research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Colgate-Palmolive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Colgate-Palmolive's overall financial health at a glance.
Interested In Other Possibilities?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
- The latest GPUs need a type of rare earth metal called Terbium and there are only 27 companies in the world exploring or producing it. Find the list for free.
- Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com